Insights on the immunogenicity of antibody-drug conjugates

Bioanalysis

Volumn 7, Issue 13, 2015, Pages 1565-1568

  Carrasco Triguero, Montserrat ^a  

^a GENENTECH INC   (United States)

Author keywords

anti drug antibodies; anti therapeutic antibodies; antibody drug conjugate; immunogenicity; immunogenicity characterization; risk assessment

Indexed keywords

ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; CYTOTOXIC AGENT; DRUG ANTIBODY; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE;

CHEMOLUMINESCENCE; CONJUGATION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCHEMILUMINESCENCE ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNOGENICITY; INFUSION RELATED REACTION; REVIEW; RISK ASSESSMENT; CHEMISTRY; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES;

EID: 84938354107     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.86     Document Type: Review

References (17)

1. Mack F, Ritchie M, Sapra P. The next generation of antibody drug conjugates. Semin. Oncol. 41(5), 637-652 (2014
2. Shen BQ, Xu K, Liu L et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjug. Nat. Biotechnol. 30, 184-652 (2012
3. Janeway CA Jr, Travers P, Walport M, Schlomchik M. Immunobiology: The Immune System In Health And Disease (6th Edition). Lawrence E, Bushell G, Morales M (Eds). Garland Science Publishing, NY, USA (2005
4. Gorovits B, Wakshull E, Pillutla R, Xu Y, Manning MS, Goyal J. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics. J. Immunol. Methods 408, 1-12 (2014
5. Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 17(1), 35-43 (2015
6. FDA. Guidance for industry, immunogenicity assessment for therapeutic protein products (2014). www.fda.gov
7. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008
8. Shankar G, Devanaravan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008
9. Brentuximab vedotin: summary of product characteristics, EMEA (2012). www.ema.europa.eu
10. Carrasco-Triguero M, Yi JH, Dere R et al. Immunogenicity assays for antibody-drug conjugates: case study with adotrastuzumab emtansine. Bioanalysis 5(9), 1007-1023 (2013
11. Carrasco-Triguero M, Mahood C, Milojic-Blair M et al. Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic. Bioanalysis 4(16), 2013-2016 (2012
12. Hoofring SA, Lopez R, Hock MB et al. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis 5(9), 1041-1055 (2013
13. Wyeth-Ayerst. Gemtuzumab/ozogamicin, product insert. (2005) www.fda.gov.
14. Yacoby I, Benhar I. Targeted anti bacterial therapy. Infect. Disord. Drug Targets 7(3), 221-229 (2007
15. Graversen JH, Svendsen P, Dagnaes-Hansen F et al. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol. Ther. 20(8), 1550-1558 (2012
16. Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Sitespecific antibody drug conjugates for cancer therapy. MAbs 6(1), 34-45 (2014
17. Deonarain MP, Yahioglu G, Stamat J, Marklew J. Emerging formats for next-generation antibody drug conjugates. Expert Opin. Drug Discov. 10(5), 463-481 (2015